Aprea Therapeutics, Inc.
Datakwaliteit: 83%
APRE
Nasdaq
Manufacturing
Chemicals
€ 0,72
▲
€ 0,02
(2,62%)
Marktkapitalisatie: 8,25 M
Prijs
€ 0,72
Marktkapitalisatie
8,25 M
Dagbereik
€ 0,67 — € 0,74
52-Weeksbereik
€ 0,55 — € 2,22
Volume
103.832
Openen € 0,74
50D / 200D Gem.
€ 0,75
4,26% below
50D / 200D Gem.
€ 1,24
41,81% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -12,91 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-103,58%
Onder sectorgemiddelde (-53,41%)
ROIC-81,10%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio5,20
Interest CoverageN/A
Waardering
PE (TTM)
-0,65
Boven sectorgemiddelde (-1,48)
P/B Ratio0,76
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,7 | -1,5 |
| P/B | 0,8 | 1,6 |
| ROE % | -103,6 | -53,4 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -12,60 M |
| ROE | -103,58% | ROA | -79,67% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -12,91 M |
| ROIC | -81,10% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 5,20 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 11,26 M | Tangible Book Value | 10,91 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,65 | Forward P/E | N/A |
| P/B Ratio | 0,76 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -156,56% | ||
| Market Cap | 8,25 M | Enterprise Value | -5,47 M |
| Per Share | |||
| EPS (Diluted TTM) | -1,93 | Revenue / Share | N/A |
| FCF / Share | -1,13 | OCF / Share | -1,13 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 102,46% |
| SBC-Adj. FCF | N/A | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -12,60 M | -12,96 M | -14,29 M | -112,66 M | -37,13 M |
| EPS (Diluted) | -1,93 | -2,45 | -3,95 | -68,16 | -1,74 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -13,23 M | -14,32 M | -15,47 M | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | — | — | 23,90 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 21.715,0 | 22.318,0 | 7.052,0 | 4.403,0 | 12.829,0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 15,93 M | 23,98 M | 22,65 M | 30,16 M | 56,82 M |
| Total Liabilities | — | — | — | 3,20 M | 7,32 M |
| Shareholders' Equity | 12,44 M | 19,31 M | 16,95 M | 25,64 M | 49,51 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 14,60 M | 22,85 M | 21,61 M | 28,79 M | 53,08 M |
| Current Assets | 15,56 M | 23,58 M | 22,52 M | 30,15 M | 56,58 M |
| Current Liabilities | 2,76 M | 3,36 M | 4,39 M | 3,20 M | 7,32 M |
{"event":"ticker_viewed","properties":{"ticker":"APRE","listing_kind":"stock","pathname":"/stocks/apre","exchange":"Nasdaq","country":"US"}}